Insulin Initiation and Intensification. Disclosure. Objectives
|
|
- Nigel Willis
- 5 years ago
- Views:
Transcription
1 Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School of Medicine Disclosure Dr. Neil Skolnik has an financial relationship or interest with a commercial entity that may have a direct interest in the subject matter of this session. Dr. Skolnik sits as part of a consultant or advisory board partnership, a Speaker s Bureaus, and receives research grants or supports. Dr. Skolnik has a relationship with AstraZeneca, Sanofi, Lilly, Teva, and Amgen. No conflict of interest exists. Objectives Review the place of Insulin in current guidelines Review initiation of insulin management Describe methods for intensifying insulin management in patients with type 2 diabetes in a clinical setting Describe new alternatives for intensification of therapy for patients who do not reach goal with the use of basal insulin 1
2 When starting Insulin in patients with Type 2 DM, the recommended way to initiate insulin is: A. Start with long acting insulin at a dose of mg/kg/d, have patient call with blood sugars for dose adjustment B. Start with long acting insulin at a dose of 10 u, if fasting Glu > 130, have patient increase Insulin by 2 u every 3 days. Follow up in office in 2 4 weeks C. Start with long acting insulin at a dose of 0.3 mg/kg/d, along with pre meal short acting insulin Consider stopping titration of basal insulin and adding additional therapy when: A. After 3 6 months of titration, A1c is greater than goal B. Fasting Glucose at target or low, and A1c greater than goal C. Daily insulin dose exceeds 0.5 u/kg/d. D. Numbers 1 and 2 above E. All of the above Case Study Question 55 year old male, weight 255 lbs with Type 2 Diabetes and hypertension is on Metformin 850 mg bid and Insulin Glargine 60 u daily daily. His A1c is 8.2 and his fasting A.M. blood sugars have been ranging from
3 Of the following choices, which would be the best recommendation: A. Accept the A1c of 8.2 B. Increase Insulin Glargine slowly over the next month to u to try to decrease his A1c C. Add an SGLT 2 inhibitor D. Add a GLP 1 Agonist Case 55 year old male with Type 2 Diabetes and hypertension. Meds: Metformin 850 mg bid; Glipizide 10 mg daily A1c 6.9 Case One year Later 55 y.o. Type 2 Diabetes,hypertension. Gained 10 pounds over the past year Meds: Metformin 850 mg bid; Glipizide 10 mg A1c 8.2 What Next? Lots of choices TZD, DPP4, GLP 1, SGLT2, Insulin Physician chose Sitagliptin 100mg daily 3
4 Case 6 m later 55 y.o. Type 2 Diabetes,hypertension. Meds: Metformin 850 mg bid; Glipizide 10 mg A1c 8.2; Sitagliptin 100mg A1c 8.0 What next? Why Basal Insulin In Type 2 Diabetes? Role of Basal Insulin in Type 2 Diabetes: Beta-cell function declines as Type 2 diabetes progresses Diagnosis Beta-cell decline exceeds 50% by time of diagnosis IGT Beta-cell 50 function (%) Postprandial 25 Hyperglycemia Type 2 Diabetes Insulin initiation Years from diagnosis Lebovitz H. Diabetes Rev 1999;7:
5 Insulin in Type 2 Diabetes Many type 2 patients will require insulin if they live long enough -5 years or more post diagnosis -A1C >8 to 9% -Function of many non-insulin meds based on presence of native insulin production by the pancreas ADA-EASD Position Statement: Management of Hyperglycemia in T2DM 3. ANTI HYPERGLYCEMIC THERAPY Therapeutic options: Insulin Rapid (Lispro, Aspart, Glulisine) Insulin level Short (Regular) Intermediate (NPH) Long (Detemir) Long (Glargine) Hours Hours after injection Basal Insulin in Type 2 Diabetes Glargine (Lantus),Detemir (Levemir), Glargine U-300 (Toujeo), Degludec (approved in Europe, not FDA approved in US) (NPH) Good, potent add-on for improved A1C Second line agent for some patients A1C >8 to 9, diabetes duration longer than 5 years 5
6 Practical Insulin Management: Starting Insulin Starting Insulin Start long acting insulin Starting Dose: 10 u or u/kg If fasting Glu > 130, increase Insulin by 2 u every 3 days. Can increase insulin by 4 u every 3 days if fasting Glu > 180 If hypoglycemia, or Fasting Glu < 70, decrease insulin by 4 u, or 10% of dose if, whichever is greater A1C < 7, continue regimen A1C 7 Diabetes Care, August 2006;29(8):1963 Diabetes Care, Dec 2008;31:1-11 What to do with Oral Meds when Starting Insulin Metformin may continue metformin less weight gain than with insulin alone SU do not improve A1c or decrease weight gain or hypoglycemia when used with insulin. Usually reasonable to stop, once insulin is started. May continue initially and then stop. TZD reduce dose or stop to avoid edema and weight gain, though may help in using less insulin in some patients. Incretin Mimetics May be helpful with insulin in decreasing weight gain and decreasing insulin dose. Increased cost. 6
7 When to Look Up After 3 6 months of titration, A1c greater than goal Fasting Glucose at target or low, and A1c greater than goal this is an indication of post prandial glucose excursion Overnight hypoglycemia The need for prandial insulin becomes more likely as the daily insulin dose exceeds 0.5u/kg/d. Moving Toward Multiple Daily Injections (MDI) As type 2 patients take larger doses of basal insulin, temptation is to split basal dose and give BID Alternative next steps : Can do basal + 1 bolus (rapid acting) Can do basal + GLP-1 Adding Bolus Insulin for Meals in Type 2 Diabetes Rapid Acting Insulin Lispro (Humalog) Aspart (Novalog) Glulisine (Apidra) Why might bolus insulin be important in some Type 2 patients? 7
8 Fasting and Postprandial Glycemic Excursions as a Function of A1C 80 Postprandial hyperglycemia Fasting hyperglycemia Contribution (%) (<7.3) Monnier L et al. Diabetes Care. 2003;26: ( ) 3 ( ) A1C (%) Quintiles 4 ( ) 5 (>10.2) Insulin Post Prandial Blood Sugar vs. Fasting Blood Sugar Basal long acting insulin best addresses fasting blood sugar Bolus rapid acting insulin addresses post prandial blood sugar 3 Ways to Intensify Insulin In Type 2 Diabetes Simple: 90/10: 2 injections 1 basal, 1 bolus (w/biggest meal) Advanced: Non-Carb Counting 1 basal, 3 boluses estimated dosing based on meal size Sophisticated: Carb-counting 1 basal, 3 boluses (+ maybe snack boluses) calculated on carb intake + premeal blood glucose value 8
9 Initiate of Basal-Bolus Therapy 90/10 rule (90% basal, 10% bolus) for 2 injection regimen (or just start with 4 u bolus) Start with largest meal of the day If A1c <8%, consider decrease basal by same number of units adding to pre-meal insulin Edelman S. Diabetes Care August 2014;37:1 9 Harris SB. Diabetes Care March 2014;37:1 7 Inzucchi S. Diabetes Care 2015;38: Titrating 90/10 Rule Targeting 2 hour post meal blood glucose (after bolus rapid acting) to <130 consistently Increase by 1 u daily if post-prandial blood glucose is over target AUTONOMY: The First Randomized Trial Comparing Two Patient Driven Approaches to Initiate and Titrate Prandial Insulin Lispro in Type 2 Diabetes Two independent, multinational, parallel, open label studies, identical in design years old Type 2 DM (study A: N = 528; study B: N = 578), On basal insulin plus oral antidiabetic drugs for 3 months HbA1c 7.0% to 12.0% Edelman S. Diabetes Care August 2014;37:
10 Optimized on insulin glargine, then randomized to one of two self titration algorithm groups adjusting lispro either: every day (Q1D) or every 3 days (Q3D) 24 weeks. Q1D algorithm: self titrated daily based on premeal glucose from the previous day; for example, when adjusting the prebreakfast dose, subjects used their prelunch reading from the day before Premeal target glucose: mg/dl. If target not achieved, increase dose 1 unit/day until target is reached. Edelman S. Diabetes Care August 2014;37: If blood glucose mg/dl, the dose was decreased by 1 unit, if < 56 mg/dl, the dose was decreased by 2 units. Edelman S. Diabetes Care August 2014;37:
11 Q3D algorithm: self titrated every 3 days based on the median blood glucose readings from the 3 days before Used average of pre meal blood glucoses Edelman S. Diabetes Care August 2014;37: Blood Glucose (mg/dl) Adjust Insulin <56 Decrease 4u Decrease 2u No change Increase 2u >145 Increase 4 u Edelman S. Diabetes Care August 2014;37: Results Both algorithms had significant and equivalent reductions in HbA1c from baseline (study A: Q3D 0.96%, Q1D 1.00% ) The incidence and rate of hypoglycemia were similar for Q3D and Q1D in both studies. Edelman S. Diabetes Care August 2014;37:
12 Take Home Point Many Methods to Increase to Multi dose Insulin Clinical Inertia in People With Type 2 Diabetes Retrospective cohort study based on 81,573 people with type 2 diabetes in the U.K. Median time from above HbA1c cutoff to intensification of Therapy Diabetes Care 36: , 2013 Time to Intensification of Therapy Baseline Regimen A1c>7.0 A1c>7.5 A1c>8.0 One Oral Agent 2.9 years 1.9 years 1.6 years Two Oral Agents 7.2 years 7.2 years 6.9 years Time to Insulin (base one, two or three oral agents) 7.1 years 6.1 years 6.0 years Diabetes Care 36: ,
13 Take home Point : When to Look Up After 3 6 months of titration, A1c greater than goal Fasting Glucose at target or low, and A1c greater than goal this is an indication of post prandial glucose excursion Overnight hypoglycemia The need for prandial insulin becomes more likely as the daily insulin dose exceeds 0.5u/kg/d. Building On Basal Bolus 2 Dose Daily Regimens Continue to add on smaller doses of bolus rapid acting (i.e., 2 to 5 units) to other meals (+snacks) with similar titration targeting 2 hour post meal blood glucose <180 Appropriate changes in basal long acting insulin dose as measured by FBS Ideally will be working toward 30-50% total daily dose of insulin as bolus rapid acting Summary Insulin Management 13
14 GLP 1 Agonists as add on to Basal Insulin Basal Insulin best addresses fasting blood glucose GLP 1 best addresses post prandial GLP 1 Agonists Generic Name Brand Name Dosing Exenatide Byetta Twice Daily Liraglutide Victoza Daily Exenatide Weekly Bydureon Weekly Albiglutide Tanzeum Weekly Dulaglutide Trulicity Weekly Comparison of Adding Albiglutide Vs. Thrice Daily Prandial Insulin Lispro for Type 2 DM Not Adequately Controlled on Basal Insulin Patients taking basal insulin (with or without oral agents) with HbA1c % (53 91 mmol/mol) entered a glargine standardization period, followed by randomization to albiglutide, 30 mg weekly (n = 282), subsequently uptitrated to 50 mg, if necessary, or thrice daily prandial lispro (n = 281) titrated while continuing metformin and/or pioglitazone. Diabetes Care August :
15 Results Change over time in mean HbA1c (A), mean FPG (B), and weight (C). Diabetes Care August : Diabetes Care August : Adverse Events Adverse Event Albiglutide Lispro Severe Hypoglycemia 0 2 Symptomatic Hypoglycemia 16% 30% Nausea 11% 1% Vomiting 7% 1% Injection Site Reactions 10% %5 Diabetes Care August :
16 Exenatide v Bolus Insulin 30 week randomized trial with 12 weeks prior insulin optimization, 627 patients with insufficient postoptimization glycated hemoglobin A1c (HbA1c) Randomized to exenatide (10 20 mg/day) or thrice daily mealtime lispro titrated both added to insulin glargine (mean 61 units/day at randomization) and metformin (mean 2,000 mg/day). Diabetes Care October : Results: Change A1c, Fasting Glucose, and Weight Diabetes Care October 2014;37: Diabetes Care October 2014;37:
17 Adverse Events GI AEs nausea, vomiting, diarrhea more common for exenatide 47% vs. Lispo 13% Hypoglycemia was greater with lispro: minor (41% Lispro vs. 30% for exenatide) confirmed nonnocturnal hypoglycemia (34% Lispro vs. 15% for exenatide) Major hypoglycemic episode Two exenatide and seven lispro recipients had at least one major hypo Diabetes Care October 2014;37: Hypoglycemia c dc1/dc140876supplementarydata.pdf Diabetes Care October 2014;37: GLP 1 Agonists and Basal Insulin GLP 1 agonist and basal insulin combination treatment can enable achievement.robust glycaemic control with no increased hypoglycaemia or weight gain. Glucagon like peptide 1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta analysis. Lancet Volume 384, No. 9961, p , 20 December
18 Everything You Need to Know In two Slides ADA/EASD Type 2 Medication Algorithm Inzucchi S. Diabetes Care 2015;38: Inzucchi S. Diabetes Care 2015;38:
19 Insulin Management Inzucchi S. Diabetes Care 2015;38: Summary Review the place of Insulin in current guidelines Review initiation of insulin management Describe methods for intensifying insulin management in patients with type 2 diabetes in a clinical setting Describe new alternatives for intensification of therapy for patients who do not reach goal with the use of basal insulin 19
20 When starting Insulin in patients with Type 2 DM, the recommended way to initiate insulin is: A. Start with long acting insulin at a dose of mg/kg/d, have patient call with blood sugars for dose adjustment B. Start with long acting insulin at a dose of 10 u, if fasting Glu > 130, have patient increase Insulin by 2 u every 3 days. Follow up in office in 2 4 weeks C. Start with long acting insulin at a dose of 0.3 mg/kg/d, along with pre meal short acting insulin Consider stopping titration of basal insulin and adding additional therapy when: A. After 3 6 months of titration, A1c is greater than goal B. Fasting Glucose at target or low, and A1c greater than goal C. Daily insulin dose exceeds 0.5 u/kg/d. D. Numbers 1 and 2 above E. All of the above Case Study Question 55 year old male, weight 255 lbs with Type 2 Diabetes and hypertension is on Metformin 850 mg bid and Insulin Glargine 60 u daily daily. His A1c is 8.2 and his fasting A.M. blood sugars have been ranging from
21 Of the following choices, which would be the best recommendation: A. Accept the A1c of 8.2 B. Increase Insulin Glargine slowly over the next month to u to try to decrease his A1c C. Add an SGLT 2 inhibitor D. Add a GLP 1 Agonist 21
Initiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationWhat to Do After Basal Insulin
BasalINSULIN What to Do After Basal Insulin 3 Treatment Strategies for Type 2 Diabetes These strategies can help you optimize glucose control in your patient with type 2 diabetes when basal insulin alone
More informationDiabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items
Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Hayley A. Miller, MD Physician, Internal Medicine, Diabetes and Metabolism, Sandy Clinic, Intermountain Healthcare Objectives:
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationINSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION
INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott
More informationIntensification of Diabetic Therapy. Case studies
Intensification of Diabetic Therapy Case studies Patient #1 1 st visit: 64 year old male, H/O prediabetes, lost weight 280 lbs. to 240 lbs. ER for dental abscess, glucose >300 A1C 11.4%, no diabetic medication,
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More informationCURRENT STATEGIES IN DIABETES MELLITUS DIABETES. Recommendations for Adults CURRENT STRATEGIES IN DIABETES MELLITUS. Diabetes Mellitus: U.S.
CURRENT STATEGIES IN DIABETES MELLITUS Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Diabetes Mellitus: U.S. Impact ~1 Million Type 1 DIABETES 16.7 Million IFG (8.3%) 12.3
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationInsulin and Post Prandial
Insulin and Post Prandial Pr Luc Martinez PCDE Meeting Barcelona 2016 Conflicts of interest disclosure Advis consultant f Amgen Inc.; AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Ipsen; Lilly; Mayoly
More informationType 2 Diabetes Mellitus Insulin Therapy 2012
Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationnocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded
Clinical Trial Design/ Primary Objective Insulin glargine Treat-to-Target Trial, Riddle et al., 2003 (23) AT.LANTUS trial, Davies et al., 2005 (24) INSIGHT trial, Gerstein et al., 2006 (25) multicenter,
More information4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis
HOW TO REGULATE DIABETES MEDICATIONS By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE Diagnosis 1 NORMAL BODY The normal pancreas releases one unit of insulin every hour all day. The normal pancreas
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationCASE A2 Managing Between-meal Hypoglycemia
Managing Between-meal Hypoglycemia 1 I would like to discuss this case of a patient who, overall, was doing well on her therapy until she made an important lifestyle change to lose weight. This is a common
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationLearning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C
UPDATES IN TYPE 2 DIABETES David Doriguzzi, PA-C Learning Objectives Upon completion of this educational activity, the participant should be able to: Overcome barriers and attitudes that limit Clinician/Patient
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationNew Therapies for Diabetes Management: Hope or Headache?
New Therapies for Diabetes Management: Hope or Headache? Elizabeth Stephens, MD, FACP PMG- Endocrinology Elizabeth.Stephens@providence.org November 2018 Disclosures None 1 Objectives Discussion of 3 rd
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationObjectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)
How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationProgressive Loss of β-cell Function in T2DM
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of November 2015. The content and views presented in this educational activity are those of
More informationYour Chart Review Data. Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine
Your Chart Review Data Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine Participation 243 registered for the program 98 have completed the Practice
More informationIndividualizing Care for Patients with Type 2 Diabetes
Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches
More informationSelecting GLP-1 RA Treatment
Selecting GLP-1 RA Treatment Dr Felicity Kaplan March 2017 Objectives Review the progressive nature of type 2 diabetes Understand the need for timely treatment intensification Examine the place of GLP-1
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationCURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2013 BMI
More informationDiabetes Management: A diagnostic perspective
Diabetes Management: A diagnostic perspective Images: http://www.engadget.com/2009/09/23/bayer-introduces-countour-usb-glucose-meter/ http://www.medtronicdiabetes.com/treatment-and-products/minimed-530g-diabetes-system-with-enlite
More information2018 Diabetes Summit Managing Diabetes: An Art and a Science
2018 Diabetes Summit Managing Diabetes: An Art and a Science Natasha Petry, PharmD, BCACP NDSU College of Health Professions, School of Pharmacy, Department of Pharmacy Practice Patient-Centered Medical
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationAdvances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D
Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies Module D 1 Learning Objectives Apply the principles of the comprehensive diabetes algorithms to patients with
More informationDEMYSTIFYING INSULIN THERAPY
DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING
More informationAlbiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes
St. Onge et al. Medical Research Archives, vol. 5, issue 11, November 2017 issue Page 1 of 10 REVIEW ARTICLE Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes Erin St. Onge 1*, Shannon
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationAdvanced Practice Education Associates. Endocrine
Advanced Practice Education Associates Endocrine Overview Diabetes Thyroid Disease 162 Copyright 2016 Advanced Practice Education Associates DIABETES MELLITUS What is the BMI cut point for screening adults
More informationManagement of Diabetes Mellitus: A Primary Care Perspective
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationClinical Practice Guidelines
Clinical Practice Guidelines Diabetes Objective The purpose is to guide the appropriate diagnosis and management of Diabetes. This guideline is designed to assist the clinician by providing a framework
More informationNew Therapies for Diabetes
Type 2 diabetes is increasingly prevalent New Therapies for Diabetes Lynn Mack, M.D. Associate Professor Diabetes, Endocrinology, & Metabolism The Nebraska Medical Center lmack@unmc.edu No Conflicts of
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More informationLilly Diabetes: Pipeline Update
Lilly Diabetes: Pipeline Update June 16, 2014 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ
More informationPosition Statement of ADA / EASD 2012
Management of Hyperglycemia in Type2 Diabetes: A Patient- Centered Approach Position Statement of ADA / EASD 2012 Cause of : Type 2 diabetes Cardiovascular disorders Blindness End-stage renal failure Amputations
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationHow they work and when to take them. Diabetes Medications
How they work and when to take them Diabetes Medications BIGUANIDES Metformin Actions Slows down the release of glucose from the liver. Helps the bodies cells become more sensitive to insulin. Pros Weight
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationThe New Age of Insulin: Exploring the Latest Trends in Insulin Therapy. The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy
The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Director of Experiential Education Associate Professor of Pharmacy Practice Midwestern
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationManagement of Diabetes Mellitus: A Primary Care Perspective. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationBrigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol
Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationThe Alphabet Soup of Diabetes. Egils Bogdanovics M.D. Hungerford Diabetes Center
The Alphabet Soup of Diabetes Egils Bogdanovics M.D. Hungerford Diabetes Center Insulin: January 11, 1922 12 year old Leonard Thompson, on a starvation diet for 2 years received his first insulin injection
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationThe Diabetes Guidelines Trek: The Next Generation. Inpatient Diabetes Guidelines. Learning Objectives. Current Inpatient Guidelines
The Diabetes Guidelines Trek: The Next Generation J. Christopher Lynch, PharmD, BCACP Southern Illinois University Edwardsville School of Pharmacy Susan Cornell BS, PharmD, CDE, FAPhA, FAADE Midwestern
More informationInpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy
Inpatient Management of Diabetes Mellitus Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy 2 Disclosure Jessica Garza does not have any actual or potential conflicts of
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix
Diabetes Medications Diabetes Medications Type 1 Insulin is needed Type 2 Oral Diabetes Medications Or Oral Diabetes Medications plus Insulin Or Insulin Alone Diabetes Medications Secretagogues Glipizide
More informationOptimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes
Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes Philip Raskin, MD Professor of Medicine The University of Texas, Southwestern Medical Center NAMCP Spring
More informationInjectable Agents for Type 2 Diabetes. Richard Christensen, MD AACE Diabetes Day, Boise, ID September 2017
Injectable Agents for Type 2 Diabetes Richard Christensen, MD AACE Diabetes Day, Boise, ID September 2017 Financial Disclosures Sanofi speaker honoraria No other relevant financial disclosures Injectable
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationJonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical
Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationCollaborative Practice Agreement
Collaborative Practice Agreement [community pharmacy name] [address] [phone number] [physician practice] [address] [phone number] Effective: [date] Expiration: [date] 1 Table of Contents 1.0 Introduction...4
More informationDiabetes Update 10/12/2017. Section #1 OBJECTIVE. Lab features to consider:
Section #1 OBJECTIVE Diabetes Update Fall 2017 Lyle Myers BE ABLE TO DIFFERENTIATE TYPE 1 FROM TYPE 2 DIABETES Clinical features: - age at onset - body weight/bmi - family history - treatment history -
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationAPPENDIX American Diabetes Association. Published online at
APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no
More information7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine
Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Participation in investigator initiated clinical research supported by: Merck Boehringer Ingelheim Novo Nordisk Astra Zeneca
More informationCOPYRIGHT. Advancing to Insulin Replacement Therapy: When, Why, and How? Update in Internal Medicine December 5, Richard S.
Advancing to Insulin Replacement Therapy: When, Why, and How? Update in Internal Medicine - 2016 December 5, 2016 Richard S. Beaser, MD Medical Director, Professional Education Joslin Diabetes Center Associate
More informationWhat s New? An Antihyperglycemic Medications Update
What s New? An Antihyperglycemic Medications Update WADE 2016 Annual Conference Josh Neumiller, PharmD, CDE, FASCP Associate Professor Department of Pharmacotherapy Washington State University Disclosures
More informationObjectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment
Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Judy Thomas, MSN, FNP-BC Holt and Walton, Rheumatology and Endocrinology Objectives Upon completion of this session you will be better
More informationDiabetes Mellitus in Older Adults. Presenter Disclosure Information
Diabetes Mellitus in Older Adults Medha Munshi, M.D. Joslin Diabetes Center Beth Israel Deaconess Medical Center Harvard Medical School Presenter Disclosure Information Medha Munshi Research grant from
More informationSilvio E. Inzucchi MD Section of Endocrinology Yale School of Medicine
Gegia Chapter of the American Association of Clinical Endocrinologists, 2017 Annual Meeting January 28, 2017 Silvio E. Inzucchi MD Section of Endocrinology Yale School of Medicine DIABETES MANAGEMENT GUIDELINES
More informationVipul Lakhani, MD Oregon Medical Group Endocrinology
Vipul Lakhani, MD Oregon Medical Group Endocrinology Disclosures None Objectives Be able to diagnose diabetes and assess control Be able to identify appropriate classes of medications for diabetes treatment
More information